DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Dr. Villy Valcheva, CEO of GH Research, expressed optimism about the trial's results, stating, "Today, as we share our unprecedented positive Phase 2b data, we celebrate a significant milestone in our ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

A new treatment being offered by High Plains Mental Health Center is proving to be life-changing for some people suffering ...

TMS services are available at the Hays Main Office of High Plains Mental Health Center, 208 E. Seventh St. For more ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.